Article
mRNA Therapies in Oncology: Key Pipeline Developments and Clinical Trial Insights
IQVIA Pipeline Link / Trial Link
Nov 25, 2024
Download

In recent years, the field of RNA therapeutics has evolved as a ground-breaking approach in medical research. Notably, the 2023 Nobel Prize in Physiology or Medicine was awarded for groundbreaking work on base modification, a critical discovery that enabled the development of COVID-19 vaccines. Following this achievement, focus has now turned to leveraging RNA's intrinsic immune-activating potential for oncology, with mRNA therapies taking the lead. mRNA therapies offer unique benefits over conventional therapies like recombinant proteins and plasmid DNA, including non-integrating, cell-free production, enhanced specificity, and potency, as well as a personalized, patient-focused approach.

Additionally, mRNA therapies possess ability to target undruggable targets with minimal side effects, setting them apart from conventional approaches. Few mRNA therapies are entering late-stage clinical development, including, Gritstone bio's GRANITE and Moderna's personalized cancer vaccine mRNA-4157, which are leading the way and are expected to enter the market in Q2 2027 and Q3 2030 respectively, according to IQVIA Pipeline Link.

This article provides an update on current mRNA based therapies for oncology and outlines the latest development activities, including ongoing clinical trials of key experimental drugs with data sourced from IQVIA Pipeline Link and IQVIA Trial Link.  

Download the article for more details and to explore the latest advancements in RNA therapeutics and their impact on cancer treatment in our article. Learn about the benefits of mRNA therapies, key developments, and ongoing clinical trials.

Related solutions

Contact Us